Pharmaceutical R&D: an age of change?

Abstract

Future Medicinal ChemistryVol. 6, No. 10 OpinionPharmaceutical R&D: an age of change?John J BaldwinJohn J BaldwinHua Medicine, Shanghai, China; E-mail Address: sixmilecross@verizon.netSearch for more papers by this authorPublished Online:31 Jul 2014https://doi.org/10.4155/fmc.14.69AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: alliancesChinaeconomic strategiesgeneric competitionoutsourcingpricing structurerate of returnReferences1 Baldwin J. Is drug discovery dead? Future Med. Chem. 3(15), 1873–1876 (2011).Link, CAS, Google Scholar2 Mullen R. The future is now. Chem. Eng. News 91(49), 12–17 (2013).Crossref, Google Scholar3 Weinstein D. FDA's 2013 so far: 26 approvals. Medical Marketing and Media, 12 December (2013).Google Scholar4 Nearly 400 drugs in development for infectious diseases. www.pharmatech.com/pharmatech/Business/nearly-400-Drugs-in=Development-for-Infectious DiseasesGoogle Scholar5 PhRMA: more than 200 innovative medicines in development for heart disease and stroke. www.pharmalive.com/pharma-morethan200-innovative-medicines-in-development-for-heart-disease and stroke=?cid=nl_pharma_dailyGoogle Scholar6 PhRMA: drug companies have 444 medicines under development for neurological disorders. www.drugstoresnews.com/article/phrma-drug-companies-have-444-medicines-under-development-neurological-disorders?ad-latest-news.Google Scholar7 Robust biopharmaceutical pipeline offers new hope for patients. www.pharmalive.com/Robust-Pipeline-offers-New-Hope-for-PatientsGoogle Scholar8 Pal S. US pharmacist, shifts in the generic-drug market: trends and causes. US Pharm. 38(6), 6–10 (2013).Google Scholar9 Silverman E. Will the affordable care act give drugmakers a boost? Pharma and Healthcare, 26 December (2013).Google Scholar10 Trenton NJ. US prescriptions drug spending drops for first time in 58 years. CBS, 9 May (2013).Google Scholar11 Edney A, Larkin C. Drug approval reach 15 year high on smoother. FDA Reviews, 2 January (2013).Google Scholar12 Sonofi, regeneron drug cuts LDL in Phase III study. www.pharmalive.com/sanofi-regeneron-drug-cuts-ldl-in-phase-iiistudy?cid=nl.phrm02Google Scholar13 Merck, Glaxo start renal cancer trial. www.pharmalive.com/merck-glaxo-start-renal-cancertrial.Google Scholar14 Sell D. The Inquirer, GSK explores potential of bioelectronic devices. 22 December (2013).Google Scholar15 World Pharmaceutical Markets. The Challenge of the Chinese Pharmaceutical Market Quarter IV 2005 Espicom Business Intelligence. Lincoln House, Chichester, UK (2005).Google Scholar16 Genetic Engineering and Biotechnology News. Asia rises as U.S. share of global research funding falls. GEN News Highlights, 2 January (2014).Google Scholar17 Daverman R, Yeo T. China Investment 2013: Up, Up and Away: a five year analysis of investment activity in China's life science industry 2008–2012. China Bio LLC, Shanghai, China (2013).Google Scholar18 Herper M. The truly staggering cost of inventing new drugs. Pharma and Healthcare, 10 February (2012).Google Scholar19 Silverman E. Are drugmakers earning returns on their R&D investments. Pharma and Healthcare, 15 December (2013).Google Scholar20 Zamek-Gliszczynski M, Hoffmaster K, Tweedlie D, Giacomini K, Hillgien J. Highlights from the International Transporter Consortium Second Workshop. Clin. Pharmacol. Ther. 92(5), 553–556 (2012).Crossref, Medline, CAS, Google Scholar21 Benet L. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J. Pharm. Sci. 102(1) 34–42 (2012).Crossref, Medline, Google Scholar22 Staton T. China hits big pharma meds with 15%-plus price cuts. Fierce Pharma, 8 January (2013).Google Scholar23 China significantly ratchets back drugs on ‘essential drugs’ list. www.fiercepharma.com/china-significantly-ratchets-backdrugs/2012-08-20Google ScholarFiguresReferencesRelatedDetails Vol. 6, No. 10 Follow us on social media for the latest updates Metrics Downloaded 114 times History Published online 31 July 2014 Published in print June 2014 Information© Future Science LtdKeywordsalliancesChinaeconomic strategiesgeneric competitionoutsourcingpricing structurerate of returnFinancial & competing interests disclosureJJ Baldwin has an association with Hua Medicine and CarysBio along with stock holdings with several US pharma. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download